You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Artificially Intelligent Diabetes Assistant (AIDA) for African Americans with Type 2 Diabetes
SBC: TARHEELVENTURES.COM, INC. Topic: 102PROJECT ABSTRACT Diabetesa chronic disease associated with significant morbidity and mortalityis disproportionately represented in African AmericansDiabetes self management education and supportDSME Sis crucial to delaying or preventing disease progressionhoweverlack of access to proper healthcare due to financialculturalknowledgegeographicor physical barriers places this disadvantaged population ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Developing therapeutic inhibitors of CIB1 for breast cancer
SBC: Reveris Therapeutics Topic: 102DESCRIPTIONprovided by applicantBreast cancer is the most common malignancy in women living in the USwith more thannew cases diagnosed each yearand an estimatedwomen dying from the disease inGreater thanof these diagnoses are classified as triple negative breast cancerTNBCwhich is considered among the most aggressive breast cancer sub typeswith the worst prognosisTNBC is difficult to treat because ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Ultrasound Based Device to Guide Treatment of Graft Versus Host Disease Using Skin Elasticity as a Biomarker
SBC: Microelastic Ultrasound Systems, Inc. Topic: 102Ultrasound Based Device to Guide Treatment of Graft Versus Host Disease using Skin Elasticity as a Biomarker ABSTRACT Sclerotic chronic graft versus host disease cGVHD develops in of allogenic Human Stem Cell Transplant HCT recipients and is associated with significant morbidity and mortality GVHD is treated with immunosuppression which puts patients at severe risk of infection ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Creation of animal models of mitochondrial DNA disease for translational research applications
SBC: ENZERNA BIOSCIENCES LLC Topic: 400Mitochondria are the principal generators of cellular ATP by oxidative phosphorylation which links electron transport via Complexes I through IV to production of ATP via ATP synthase Over pathogenic human mitochondrial DNA mtDNA mutations associated with diseases ranging from cardiomyopathy to juvenile blindness have been identified Collectively millions are affected by mtDNA disease fo ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Developing Heparan Sulfate Glycan Array
SBC: GLYCAN THERAPEUTICS CORPORATION Topic: NIGMSProject titleDeveloping heparan sulfate glycan array This proposal is aimed at developing a high throughput method to study the interactions between heparan sulfateHSand proteinsHS is a highly sulfated polysaccharide displaying a wide range of biological functionsGlycan Therapeutics is a company specialized in HS related research productsIn this proposalan HS array technique will be constructed us ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of a POEGMA Aptamer rapid onset anticoagulant that eliminates antigenicity to anti PEG antibodies
SBC: Gateway Bio, Inc. Topic: NHLBIABSTRACT The objective of this STTR proposal is to reformulate a promising PEG aptamer rapid onset anticoagulant ROA by applying a novel PEG like POEGMA polymer brush technology capable of eliminating anti PEG antigenicity The importance of this proposal is highlighted by the early termination of a recent Phase III clinical trial of the original PEG aptamer conjugate in which severe allergic ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
BurntOut Role Play Simulation for Building Medical Student Resiliency
SBC: Clinical Tools, Inc Topic: 400We propose to produce a simulation experience to ensure that clinical year medical students are prepared for have coping strategies to deal with and are more resilient to the stresses and challenges that await them as they transition to clinical practice and learning in a clinical environment The experience will guide institutional level change by anonymously communicating studentsandapos conc ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
A D osteoarthritis model targeting patient populations with high risk genetic polymorphisms
SBC: Cytex Therapeutics, Inc. Topic: NIAMSAbstract Osteoarthritis OA is a degenerative joint disease that affects an estimated million adults in the United States and results in an economic burden of over $ billion per year Although the burden of OA is immense current non surgical treatments are only palliative and no disease modifying OA drugs DMOADs presently exist to address the problem This lack of success in identifying ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Novel Antigen-Specific Immunomodulatory Tregitope-based Therapy to Address Autoimmune Pathogenesis in Graves' Disease
SBC: EPIVAX, INC. Topic: 200ABSTRACT SignificanceGravesdiseaseGDone of the most prevalent autoimmune diseasesis caused by stimulating autoantibodiesTSAbto the Thyroid Stimulating Hormone ReceptorTSHRresulting in hyperthyroidismCurrent methods for managing hyperthyroidism in GD target excess thyroid hormone secretion by ablation or removal of the thyroid or by blocking thyroid hormone synthesisEach of these therapies is assoc ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
AML MutationCounter a tool to detect residual and recurrent leukemia
SBC: Asystbio Laboratories, LLC Topic: 102Abstract AsystBio LLC proposes to market a molecular tool kit called AML MutationCounter to count somatic mutations in genes that contribute to the development of acute myeloid leukemia AML We have developed a set of reagents and computer programs for application of next generation sequencing to count AML gene mutations The tool kit is versatile and can be used with either of the two major DNA ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health